ENRIQUE LIRAG: Open Payments
NPI 1932200219 · ALLENTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,787 in 132 payments from 12 companies in 2025. Trend: 2023 $1,566 · 2024 $2,205 · 2025 $2,787
Food & beverage: $2,787
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $563 |
| E.R. Squibb & Sons, L.L.C. | 21 | $462 |
| ABBVIE INC. | 17 | $340 |
| Vanda Pharmaceuticals Inc. | 11 | $250 |
| Teva Pharmaceuticals USA, Inc. | 13 | $249 |
| Janssen Pharmaceuticals, Inc | 14 | $243 |
| Lundbeck LLC | 11 | $218 |
| Neurocrine BioSciences, Inc. | 8 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $126 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
Products named: COBENFY, ARISTADA, VRAYLAR, REXULTI, FANAPT, INVEGA SUSTENNA, INGREZZA, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
